|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsor: | Sanofi-Aventis |
|---|---|
| Information provided by: | Sanofi-Aventis |
| ClinicalTrials.gov Identifier: | NCT00501384 |
Purpose
The primary objective is to determine the optimal dose or range of doses of SR121463B for the reduction in recurrence of ascites, when used concomitantly with a standard dose regimen of spironolactone.
The secondary objective was to determine the tolerability of different fixed doses of SR121463B in cirrhotic ascites, over a 12-week treatment period.
This SPA study is followed by a single-blind, placebo-controlled, 40 weeks long-term safety extension (ExSPA). The first extension is followed by another long-term study (PASCCAL-1).
| Condition | Intervention | Phase |
|---|---|---|
|
Ascites Liver Cirrhosis |
Drug: satavaptan (SR121463B) |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Study for the Prevention of Ascites (SPA): Comparison of Fixed Doses of SR121463B Versus Placebo in the Reduction of Recurrence of Cirrhotic Ascites |
| Enrollment: | 151 |
| Study Start Date: | April 2004 |
| Study Completion Date: | May 2005 |
| Primary Completion Date: | May 2005 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Contacts and Locations| Argentina | |
| Sanofi-aventis Administrative Office | |
| Buenos Aires, Argentina | |
| Australia, New South Wales | |
| Sanofi-aventis Administrative Office | |
| Cove, New South Wales, Australia | |
| Belgium | |
| Sanofi-aventis Administrative Office | |
| Diegem, Belgium | |
| Canada, Quebec | |
| Sanofi-aventis Administrative Office | |
| Laval, Quebec, Canada | |
| Croatia | |
| Sanofi-aventis Administrative Office | |
| Zagreb, Croatia | |
| Czech Republic | |
| Sanofi-aventis Administrative Office | |
| Praha, Czech Republic | |
| France | |
| Sanofi-aventis Administrative Office | |
| Paris, France | |
| Germany | |
| Sanofi-aventis Administrative Office | |
| Berlin, Germany | |
| Italy | |
| Sanofi-aventis Administrative Office | |
| Milano, Italy | |
| Spain | |
| Sanofi-aventis Administrative Office | |
| Barcelona, Spain | |
| Taiwan | |
| Sanofi-aventis Administrative Office | |
| Taipei, Taiwan | |
| Study Director: | ICD CSD | Sanofi-Aventis |
More Information
| Responsible Party: | sanofi-aventis ( ICD Study Director ) |
| Study ID Numbers: | DFI4522, LTS5635, LTS10209 |
| Study First Received: | July 13, 2007 |
| Last Updated: | January 9, 2009 |
| ClinicalTrials.gov Identifier: | NCT00501384 History of Changes |
| Health Authority: | United States: Food and Drug Administration; Canada: Health Canada; Spain: Spanish Agency of Medicines; Italy: Ministry of Health |
|
cirrhotic ascites |
|
Liver Diseases Digestive System Diseases Pathologic Processes |
Fibrosis Ascites Liver Cirrhosis |
